Melanoma Therapy via Activated T-Cells From Patients Could Work: Study

• comments
• 
• 

Good news for melanoma patients as findings in a study demonstrate that T-cells derived from patients with melanoma can generate a protective immunity response against the disease. This is according to a study led by Dr. Julian Kim, MD, Chief Medical Officer of UH Seidman Cancer Center as published in the July/August issue of the Journal of Immunotherapy.

To better understand this astounding study, it is best that a certain knowledge of T-cell is also understood. T-cells, according to Tcells.org, are essential for human immunity.

It is a type of white blood cell that circulates in the body. The T cells are also dubbed to have x-ray vision as it can scan the intracellular environment for cells that are infected and eradicate them directly. In this same manner, cancer cells can be detected by the T cells and can even be prevented. 

Because of T cells and the responses it generates in the immune system, almost all autoimmune diseases can be detected, even organs that are not compatible during transplants. 

Thus, it is nothing but good development that new findings suggest T cells derived from the lymph nodes of patients with melanoma can be multiplied and activated in the laboratory. It will then be administered intravenously when given to patients.

The T-cells are taken from the lymph nodes because this is where the immune response is naturally detected against pathogens, including that of cancer. Once these T cells are cultured and activated, they will then be transferred to the same patient, activating the immune system for a proper response in attacking the cancer directly. 

Adoptive immunotherapy is the term referring to this novel approach of cancer treatment. It involves the removal of the lymph nodes by surgery so that researchers can monitor the growth and process of the T-Cells. While this may be of substantial advantage to a lot, it is not offered to a lot of institutions around the globe, ScienceDaily notes. 

The human clinical trial is now being supported by University Hospitals as well as many philanthropic efforts. It is funded by the National Institutes of Health and Case Comprehensive Cancer Center.

The promising results is deemed to be a good potential for the treatment of cancer patients, not just those with melanoma. Intended for widespread use if results continue to have a good promise, Dr. Kim and his team are planning to combine these T cells with other immune therapies which will hopefully and eventually result in a cure. The team will also venture into studying other types of tumor.